FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2961683485> ?p ?o ?g. }

• W2961683485 abstract "Lichen planus (LP) is a common, chronic relapsing inflammatory disorder of the skin and mucous membranes which often poses a major therapeutic challenge due to its refractory course. Novel pathogenesis-based therapies are urgently needed. As several studies have shown that IL-17 may contribute to LP pathogenesis, we investigated whether therapeutic targeting of IL-17+ T cells leads to clinical improvement of mucosal and cutaneous LP lesions. A total of 5 patients with lichen planus were treated in a compassionate use trial with either secukinumab (anti-IL-17; 3 patients with acute and chronic recalcitrant muco-cutaneous LP), ustekinumab (anti-IL-12/IL-23; 1 patient with recalcitrant oral LP) or guselkumab (anti-IL-23; 1 patient with recalcitrant oral LP). The clinical course of the patients was assessed by the Autoimmune Bullous Skin Disorder Intensity Score (ABSIS) reflecting both extent and severity of disease and functional sequelae of oral involvement for at least 12 weeks. The inflammatory infiltrate in lesional and post-lesional skin was analyzed by immunohistochemistry before and after treatment. Furthermore, the cytokine profile of peripheral blood T cells from the treated patients was assessed by flow cytometry and/or ELISpot assay. Treatment with secukinumab induced rapid and prolonged clinical amelioration of muco-cutaneous LP. Clinical improvement was accompanied by a strong reduction of the Th1 and Th17/Tc17 cellular mucosal and cutaneous infiltrate. Moreover, long-term treatment of one patient with recalcitrant oral LP with ustekinumab led to healing of the ulcerative oral lesions and a reduction of peripheral blood and lesional IL-17+ T cells. Finally, treatment with guselkumab led to a marked clinical improvement in a patient with recalcitrant erosive oral LP. These findings show for the first time that therapeutic targeting of Th17/Tc17 cells leads to a pronounced clinical amelioration of mucosal and cutaneous LP and strongly suggests that IL-17-producing T cells are central to disease pathogenesis. Thus, therapeutic targeting of Th17/Tc17 cells opens new therapeutic avenues in the treatment of recalcitrant LP." @default.
• W2961683485 created "2019-07-23" @default.
• W2961683485 creator A5022515383 @default.
• W2961683485 creator A5028974311 @default.
• W2961683485 creator A5034272199 @default.
• W2961683485 creator A5035909037 @default.
• W2961683485 creator A5036241222 @default.
• W2961683485 creator A5051267704 @default.
• W2961683485 creator A5052830378 @default.
• W2961683485 creator A5054050180 @default.
• W2961683485 creator A5061019810 @default.
• W2961683485 creator A5064149822 @default.
• W2961683485 creator A5066303397 @default.
• W2961683485 creator A5067729163 @default.
• W2961683485 date "2019-07-31" @default.
• W2961683485 modified "2023-10-12" @default.
• W2961683485 title "Therapeutic Targeting of Th17/Tc17 Cells Leads to Clinical Improvement of Lichen Planus" @default.
• W2961683485 cites W149143113 @default.
• W2961683485 cites W1503370241 @default.
• W2961683485 cites W1516263086 @default.
• W2961683485 cites W1539369810 @default.
• W2961683485 cites W1581121553 @default.
• W2961683485 cites W1892976117 @default.
• W2961683485 cites W1966226308 @default.
• W2961683485 cites W1973354423 @default.
• W2961683485 cites W1989588757 @default.
• W2961683485 cites W1998895238 @default.
• W2961683485 cites W2006249161 @default.
• W2961683485 cites W2014112474 @default.
• W2961683485 cites W2015347941 @default.
• W2961683485 cites W2017893786 @default.
• W2961683485 cites W2020738031 @default.
• W2961683485 cites W2029403964 @default.
• W2961683485 cites W2029628152 @default.
• W2961683485 cites W2048632710 @default.
• W2961683485 cites W2055304739 @default.
• W2961683485 cites W2077531651 @default.
• W2961683485 cites W2083915571 @default.
• W2961683485 cites W2097170399 @default.
• W2961683485 cites W2108355455 @default.
• W2961683485 cites W2151826047 @default.
• W2961683485 cites W2318956962 @default.
• W2961683485 cites W2603454965 @default.
• W2961683485 cites W2614738659 @default.
• W2961683485 cites W2616875005 @default.
• W2961683485 cites W2736731936 @default.
• W2961683485 cites W2756408557 @default.
• W2961683485 cites W2789890489 @default.
• W2961683485 cites W3014123378 @default.
• W2961683485 cites W3025075911 @default.
• W2961683485 cites W3187118014 @default.
• W2961683485 cites W4233817719 @default.
• W2961683485 doi "https://doi.org/10.3389/fimmu.2019.01808" @default.
• W2961683485 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6685396" @default.
• W2961683485 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31417572" @default.
• W2961683485 hasPublicationYear "2019" @default.
• W2961683485 type Work @default.
• W2961683485 sameAs 2961683485 @default.
• W2961683485 citedByCount "59" @default.
• W2961683485 countsByYear W29616834852019 @default.
• W2961683485 countsByYear W29616834852020 @default.
• W2961683485 countsByYear W29616834852021 @default.
• W2961683485 countsByYear W29616834852022 @default.
• W2961683485 countsByYear W29616834852023 @default.
• W2961683485 crossrefType "journal-article" @default.
• W2961683485 hasAuthorship W2961683485A5022515383 @default.
• W2961683485 hasAuthorship W2961683485A5028974311 @default.
• W2961683485 hasAuthorship W2961683485A5034272199 @default.
• W2961683485 hasAuthorship W2961683485A5035909037 @default.
• W2961683485 hasAuthorship W2961683485A5036241222 @default.
• W2961683485 hasAuthorship W2961683485A5051267704 @default.
• W2961683485 hasAuthorship W2961683485A5052830378 @default.
• W2961683485 hasAuthorship W2961683485A5054050180 @default.
• W2961683485 hasAuthorship W2961683485A5061019810 @default.
• W2961683485 hasAuthorship W2961683485A5064149822 @default.
• W2961683485 hasAuthorship W2961683485A5066303397 @default.
• W2961683485 hasAuthorship W2961683485A5067729163 @default.
• W2961683485 hasBestOaLocation W29616834851 @default.
• W2961683485 hasConcept C142724271 @default.
• W2961683485 hasConcept C156730664 @default.
• W2961683485 hasConcept C16005928 @default.
• W2961683485 hasConcept C203014093 @default.
• W2961683485 hasConcept C2776090121 @default.
• W2961683485 hasConcept C2776260265 @default.
• W2961683485 hasConcept C2777138892 @default.
• W2961683485 hasConcept C2778690821 @default.
• W2961683485 hasConcept C2778975655 @default.
• W2961683485 hasConcept C2779053233 @default.
• W2961683485 hasConcept C2779134260 @default.
• W2961683485 hasConcept C2779786854 @default.
• W2961683485 hasConcept C2780564577 @default.
• W2961683485 hasConcept C2780942790 @default.
• W2961683485 hasConcept C47348012 @default.
• W2961683485 hasConcept C71924100 @default.
• W2961683485 hasConcept C8891405 @default.
• W2961683485 hasConceptScore W2961683485C142724271 @default.
• W2961683485 hasConceptScore W2961683485C156730664 @default.
• W2961683485 hasConceptScore W2961683485C16005928 @default.
• W2961683485 hasConceptScore W2961683485C203014093 @default.
• W2961683485 hasConceptScore W2961683485C2776090121 @default.

• next